In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will get ABBV-744 and ruxolitinib. Members will get treatment till sickness progression or the contributors are unable to tolerate the study drugs. There may be greater treatment stress for individuals On this trial in comparison with https://archerxjvgr.jts-blog.com/31167459/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options